Vesiculobullous Disorders

Published on 25/03/2015 by admin

Filed under Pediatrics

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1873 times

Chapter 646 Vesiculobullous Disorders

Many diseases are characterized by vesiculobullous lesions; they vary considerably in cause, age of onset, and pattern. The morphology of the blister often provides a visual clue to the location of the lesion within the skin. Blisters localized to the epidermal layers are thin-walled, relatively flaccid, and easily ruptured. Subepidermal blisters are tense, thick-walled, and more durable. Biopsies of blisters can be diagnostic because the level of cleavage within the skin and associated findings, such as the nature of the inflammatory infiltrate, are characteristic for a particular disorder. Other diagnostic procedures, such as immunofluorescence and electron microscopy, can often help distinguish vesiculobullous disorders that have nearly identical histopathologic findings (Table 646-1).

Table 646-1 SITES OF BLISTER FORMATION AND DIAGNOSTIC STUDIES FOR THE VESICULOBULLOUS DISORDERS

DISORDER BLISTER CLEAVAGE SITE DIAGNOSTIC STUDIES
Acrodermatitis enteropathica IE Zn level
Bullous impetigo GL Smear, culture
Bullous pemphigoid SE (junctional) Direct and indirect immunofluorescence studies
Candidosis SC KOH preparation, culture
Dermatitis herpetiformis SE Direct immunofluorescence studies
Dermatophytosis IE KOH preparation, culture
Dyshidrotic eczema IE Routine histopathology
EB—simplex IE Electron microscopy; immunofluorescence mapping
EB of the hands and feet IE Electron microscopy; immunofluorescence mapping
Junctional EB (letalis) SE (junctional) Electron microscopy; immunofluorescence mapping
Recessive dystrophic EB SE Electron microscopy; immunofluorescence mapping
Dominant dystrophic EB SE Electron microscopy; immunofluorescence mapping
Epidermolytic hyperkeratosis IE Routine histopathology
Erythema multiforme SE Routine histopathology
Erythema toxicum SC, IE Smear for eosinophils
Incontinentia pigmenti IE
Insect bites IE Routine histopathology
Linear IgA dermatosis SE Direct immunofluorescence studies
Mastocytosis SE Routine histopathology
Miliaria crystallina IC Routine histopathology
Neonatal pustular melanosis SC, IE Smear for cells
Pemphigus foliaceus GL Direct and indirect immunofluorescence studies
Tzanck smear
Pemphigus vulgaris Suprabasal Direct and indirect immunofluorescence studies
Tzanck smear
Scabies IE Scraping
Staphylococcal scalded skin syndrome GL Routine histopathology
Toxic epidermal necrolysis SE Routine histopathology
Viral blisters IE

EB, epidermolysis bullosa; GL, granular layer; IC, intracorneal; IE, intraepidermal; KOH, potassium hydroxide; SC, subcorneal; SE, subepidermal.

646.1 Erythema Multiforme

Clinical Manifestations

EM has numerous morphologic manifestations on the skin, varying from erythematous macules, papules, vesicles, bullae, or urticaria-appearing plaques to patches of confluent erythema. The eruption appears most commonly in patients between the ages of 10 and 40 yr and usually is asymptomatic, although a burning sensation or pruritus may be present. The diagnosis of EM is established by finding the classic lesion: doughnut-shaped, target-like (iris or bull’s-eye) papules with an erythematous outer border, an inner pale ring, and a dusky purple to necrotic center (Figs. 646-1 and 646-2).

image

Figure 646-1 Early fixed papules with a central dusky zone on the dorsum of the hand of a child with erythema multiforme due to herpes simplex virus.

(From Weston WL, Lane AT, Morelli J: Color textbook of pediatric dermatology, ed 3, St Louis, 2002, Mosby, p 156.)

image

Figure 646-2 “Target” or “iris” lesions with characteristic central dusky zone on palms of a child with erythema multiforme due to herpes simplex virus.

(From Weston WL, Lane AT, Morelli J: Color textbook of pediatric dermatology, ed 3, St Louis, 2002, Mosby, p 156.)

EM is characterized by an abrupt, symmetric cutaneous eruption, most commonly on the extensor upper extremities; lesions are relatively sparse on the face, trunk, and legs. The eruption often appears initially as red macules or urticarial plaques that expand centrifugally to form lesions up to 2 cm in diameter with a dusky to necrotic center. Lesions of a particular episode typically appear within 72 hr and remain fixed in place. Oral lesions may occur with a predilection for the vermilion border of the lips and the buccal mucosa, but other mucosal surfaces are spared. Prodromal symptoms are generally absent. Lesions typically resolve without sequelae in about 2 wk; progression to Stevens-Johnson syndrome does not occur. EM may manifest initially as urticarial lesions, but unlike urticaria, a given lesion of EM does not fade within 24 hr.

646.2 Stevens-Johnson Syndrome

Etiology

Mycoplasma pneumoniae is the most convincingly demonstrated infectious cause of Stevens-Johnson syndrome. Drugs, particularly sulfonamides, nonsteroidal anti-inflammatory agents, antibiotics, and anticonvulsants, are the most common precipitants of Stevens-Johnson syndrome and toxic epidermal necrolysis. HLA-B*1502 and HLA-B*5801 have been implicated in the development of these two disorders in Han Chinese patients receiving carbamazepine and in Japanese patients receiving allopurinol, respectively.

Clinical Manifestations

Cutaneous lesions in Stevens-Johnson syndrome generally consist initially of erythematous macules that rapidly and variably develop central necrosis to form vesicles, bullae, and areas of denudation on the face, trunk, and extremities. The skin lesions are typically more widespread than in EM and are accompanied by involvement of two or more mucosal surfaces, namely the eyes, oral cavity, upper airway or esophagus, gastrointestinal tract, or anogenital mucosa (Fig. 646-3). A burning sensation, edema, and erythema of the lips and buccal mucosa are often the presenting signs, followed by development of bullae, ulceration, and hemorrhagic crusting. Lesions may be preceded by a flu-like upper respiratory illness. Pain from mucosal ulceration is often severe, but skin tenderness is minimal to absent in Stevens-Johnson syndrome, in contrast to pain in toxic epidermal necrolysis. Corneal ulceration, anterior uveitis, panophthalmitis, bronchitis, pneumonitis, myocarditis, hepatitis, enterocolitis, polyarthritis, hematuria, and acute tubular necrosis leading to renal failure may occur. Disseminated cutaneous bullae and erosions may result in increased insensible fluid loss and a high risk of bacterial superinfection and sepsis. New lesions occur in crops, and complete healing may take 4-6 wk; ocular scarring, visual impairment, and strictures of the esophagus, bronchi, vagina, urethra, or anus may remain. Nonspecific laboratory abnormalities in Stevens-Johnson syndrome include leukocytosis, elevated erythrocyte sedimentation rate, and, occasionally, increased liver transaminase levels and decreased serum albumin values. Toxic epidermal necrolysis is the most severe disorder in the clinical spectrum of the disease, involving considerable constitutional toxicity and extensive necrolysis of the mucous membranes and > 30% of the body surface area (Fig. 646-4).

Treatment

Management of Stevens-Johnson syndrome is supportive and symptomatic. Potentially offending drugs must be discontinued as soon as possible. Ophthalmologic consultation is mandatory because ocular sequelae such as corneal scarring can lead to vision loss. Application of cryopreserved amniotic membrane to the ocular surface during the acute phase of the disease limits the destructive and long-term sequelae. Oral lesions should be managed with mouthwashes and glycerin swabs. Vaginal lesions should be observed closely and treated to prevent vaginal stricture or fusion. Topical anesthetics (diphenhydramine, dyclonine, viscous lidocaine) may provide relief from pain, particularly when applied before eating. Denuded skin lesions can be cleansed with saline or Burrow solution compresses. Antibiotic therapy is appropriate for documented secondary bacterial infection. Treatment may require admission to an intensive care unit; intravenous (IV) fluids; nutritional support; sheepskin or air-fluid bedding; daily saline or Burow solution compresses; paraffin gauze or colloidal gel (Hydrogel) dressing of denuded areas; saline compresses on the eyelids, lips, or nose; analgesics; and urinary catheterization (when needed). A daily examination for infection and ocular lesions, which constitute the major cause of long-term morbidity, is essential. Systemic antibiotics are indicated for documented urinary or cutaneous infections and for suspected bacteremia (due to S. aureus or P. aeruginosa) because infection is the leading cause of death. Prophylactic systemic antibiotics are not necessary. Although corticosteroids are sometimes advocated in early, severe cases of Stevens-Johnson syndrome, no prospective double-blind studies evaluating their efficacy have been reported. Most authorities discourage their use because of reports of increased morbidity and mortality (sepsis) with their administration. IV immunoglobulin (IVIG) (1.5-2.0 g/kg/day × 3 days) should be considered in early disease.

Two severe cases of toxic epidermal necrolysis have been treated successfully with etanercept.

646.3 Toxic Epidermal Necrolysis

Epidemiology and Etiology

The pathogenesis of toxic epidermal necrolysis is not proved but may involve a hypersensitivity phenomenon that results in damage primarily to the basal cell layer of the epidermis. Epidermal damage appears to result from keratinocyte apoptosis (Chapter 646.2). This condition is triggered by many of the same factors that are thought to be responsible for Stevens-Johnson syndrome, principally drugs such as the sulfonamides, amoxicillin, phenobarbital, hydantoin, butazones, and allopurinol. Toxic epidermal necrolysis is defined by (1) widespread blister formation and morbilliform or confluent erythema, associated with skin tenderness; (2) absence of target lesions; (3) sudden onset and generalization within 24-48 hr; (4) histologic findings of full-thickness epidermal necrosis and a minimal to absent dermal infiltrate. These criteria categorize toxic epidermal necrolysis as a separate entity from EM.

Clinical Manifestations

The prodrome consists of fever, malaise, localized skin tenderness, and diffuse erythema. Inflammation of the eyelids, conjunctivae, mouth, and genitals may precede skin lesions. Flaccid bullae may develop, although this is not a prominent feature. Characteristically, full-thickness epidermis is lost in large sheets (see Fig. 646-4). Nikolsky sign (denudation of the skin with gentle tangential pressure) is present but only in the areas of erythema (see Fig. 646-4). Healing takes place over 14 or more days. Scarring, particularly of the eyes, may result in corneal opacity. The course may be relentlessly progressive, complicated by severe dehydration, electrolyte imbalance, shock, and secondary localized infection and septicemia. Loss of nails and hair may also occur. Long-term morbidity includes alterations in skin pigmentation, eye problems (lack of tears, conjunctival scarring, loss of lashes), and strictures of mucosal surfaces. The differential diagnosis includes staphylococcal scalded skin syndrome, in which the blister cleavage plane is intraepidermal; graft versus host disease; chemical burns; drug eruptions; toxic shock syndrome; and pemphigus.

Anticonvulsant hypersensitivity syndrome (DRESS syndrome; Chapter 637.2) is a multisystem reaction that appears approximately 4 wk to 3 mo after the start of therapy with phenytoin, carbamazepine, phenobarbitone, primidone, or other drugs, most commonly antibiotics. The mucocutaneous eruption may be identical to that of EM, Stevens-Johnson syndrome, or toxic epidermal necrolysis, but the reaction also typically includes lymphadenopathy as well as fever, hepatic, renal and pulmonary disease, eosinophilia, atypical lymphocytosis, and leukocytosis.

Treatment

Appreciation of the specific etiologic factor is crucial. When the disorder is drug induced, administration of the drug must be discontinued as soon as possible. Management is similar to that for severe burns and may be best accomplished in a burn unit (Chapter 68). It may include strict reverse isolation, meticulous fluid and electrolyte therapy, use of an air-fluid bed, and daily cultures. Systemic antibiotic therapy is indicated when secondary infection is evident or suspected. Skin care consists of cleansing with isotonic saline or Burow solution. Biologic or colloid gel (Hydrogel) dressings alleviate pain and reduce fluid loss. Narcotics are often required for pain relief. Mouth and eye care, as for EM major, may be necessary. Because of an immune mechanism, systemic glucocorticosteroids and IVIG have been used with apparent success. Nonetheless, this treatment remains controversial.

646.4 Mechanobullous Disorders

Epidermolysis Bullosa

Diseases categorized under the general term epidermolysis bullosa (EB) are a heterogeneous group of congenital, hereditary blistering disorders. They differ in severity and prognosis, clinical and histologic features, and inheritance patterns, but are all characterized by induction of blisters by trauma and exacerbation of blistering in warm weather. The disorders can be categorized under 3 major headings with multiple subgroupings: epidermolysis bullosa simplex (EBS), junctional epidermolysis bullosa (JEB), and dystrophic epidermolysis bullosa (DEB) (Table 646-2). Kindler syndrome (Kindlin-1 gene), which includes poikiloderma and photosensitivity as well as easy blistering, is also considered a separate form of EB.

Epidermolysis Bullosa Simplex

EBS is a nonscarring, autosomal dominant disorder. The defect in most common types of EBS is in keratin 5 or 14, which makes up intermediate filaments of the basal keratinocytes. The intraepidermal bullae result from cytolysis of the basal cells. There are multiple other rare variants with defects that also result in intraepidermal blistering.

In EBS—generalized other (formerly Koebner), blisters are usually present at birth or during the neonatal period. Sites of predilection are the hands, feet, elbows, knees, legs, and scalp. Intraoral lesions are minimal, nails rarely become dystrophic and usually regrow even when they are shed, and dentition is normal. Bullae heal with minimal to no scar or milia formation. Secondary infection is the primary complication. The propensity to blister decreases with age, and the long-term prognosis is good. Blisters should be drained by puncturing, but the blister top should be left intact to protect the underlying skin. Erosions may be covered with a semipermeable dressing.

EBS—localized (formerly Weber-Cockayne) predominantly affects the hands and feet and often manifests when a child begins to walk; onset may be delayed until puberty or early adulthood, when heavy shoes are worn or the feet are subjected to increased trauma. Bullae are usually restricted to the hands and feet (Fig. 646-5); rarely, they occur elsewhere, such as the dorsal aspect of the arms and the shins. The disorder ranges from mildly incapacitating to crippling at times of severe exacerbations.

EBS—Dowling-Meara (herpetiformis) is characterized by grouped blisters resembling those of herpes simplex (Fig. 646-6). During infancy, blistering may be severe and extensive, may involve mucous membranes, and may result in shedding of nails, formation of milia, and mild pigmentary changes, without scarring. After the first few months of life, warm temperatures do not appear to exacerbate blistering. Hyperkeratosis and hyperhidrosis of the palms and soles may develop, but generally, the condition improves with age.

Junctional Epidermolysis Bullosa

JEB—Herlitz is an autosomal recessive condition that is life threatening. Blisters appear at birth or develop during the neonatal period, particularly on the perioral area, scalp, legs, diaper area, and thorax. Nails eventually become dystrophic and then often permanently lost. Mucous membrane involvement may be severe, and ulceration of the respiratory, gastrointestinal, and genitourinary epithelium has been documented in many affected children, although less frequently than in severe recessive dystrophic epidermolysis bullosa (RDEB). Healing is delayed, and vegetating granulomas may persist for a long time. Large, moist, erosive plaques (Fig. 646-7) may provide a portal of entry for bacteria, and septicemia is a frequent cause of death. Mild atrophy may be seen in areas of recurrent blistering. Defective dentition with early loss of teeth as a result of rampant caries is characteristic. Growth retardation and recalcitrant anemia are almost invariable. In addition to infection, cachexia and circulatory failure are common causes of death. Most patients die within the first 3 yr of life.

JEB—non-Herlitz is a heterogeneous group of disorders. Blistering may be severe in the neonatal period, making differentiation from the Herlitz type difficult. All conditions associated with the Herlitz type may be seen but are usually milder. JEB—non-Herlitz generalized (formerly generalized atrophic benign epidermolysis bullosa) is included as a variant of non-Herlitz JEB. Another variant of non-Herlitz JEB is associated with pyloric atresia.

In all types of JEB, a subepidermal blister is found on light microscopic examination, and electron microscopy demonstrates a cleavage plane in the lamina lucida, between the plasma membranes of the basal cells and the basal lamina. Absence or a great reduction of hemidesmosomes is seen on electron micrographs in JEB—Herlitz and some cases of JEB—non-Herlitz. The defect is in laminin 332 (formerly laminin 5), a glycoprotein associated with anchoring filaments beneath the hemidesmosomes. In JEBnon-Herlitz, defects have also been described in other hemidesmosomal components, such as Col17A1. In JEB—pyloric atresia, the defect is in the α6β4 integrin.

Treatment for junctional epidermolysis bullosa is supportive. The diet should provide adequate calories and supplemental iron. Infections should be treated promptly. Transfusions of packed red blood cells may be required if the patient shows no response to iron and erythropoietin therapy. Tissue-engineered skin grafts (artificial skin derived from human keratinocytes and fibroblasts) may be beneficial.

Dystrophic Epidermolysis Bullosa

All forms of DEB result from mutations in collagen VII, a major component of anchoring fibrils that tether the basement membrane and overlying epidermis to its dermal foundation. The blister is subepidermal in all types of DEB. The type and location of the mutation dictate the severity of the phenotype.

Dominant dystrophic epidermolysis bullosa (DDEB) is the most common type of DEB. The spectrum of DDEB is varied. Blisters may be manifest at birth and are often limited and characteristically form over acral bony prominences. The lesions heal promptly, with the formation of soft, wrinkled scars, milia, and alterations in pigmentation (Fig. 646-8). Abnormal nails and nail loss are common. In many cases, the blistering process is mild, causing little restriction of activity and not impairing growth and development. Mucous membrane involvement tends to be minimal.

RDEB—severe generalized (formerly RDEB—Hallopeau-Siemens) is the most incapacitating form of epidermolysis bullosa, although the clinical spectrum is wide. Some patients have blisters, scarring, and milia formation primarily on the hands, feet, elbows, and knees (Fig. 646-9). Others have extensive erosions and blister formation at birth that seriously impedes their care and feeding. Mucous membrane lesions are common and may cause severe nutritional deprivation, even in older children, whose growth may be retarded. During childhood, esophageal erosions and strictures, scarring of the buccal mucosa, flexion contractures of joints secondary to scarring of the integument, development of cutaneous carcinomas, and the development of digital fusion may significantly limit the quality of life (Fig. 646-10).

Although the skin becomes less sensitive to trauma with aging in patients with RDEB, the progressive and permanent deformities complicate management, and the overall prognosis is poor. Foods that traumatize the buccal or esophageal mucosa should be avoided. If esophageal scarring develops, a semiliquid diet and esophageal dilatations may be required. Stricture excision or colonic interposition may be needed to relieve esophageal obstruction. In infants, severe oropharyngeal involvement may necessitate the use of special feeding devices such as a gastrostomy tube. Iron therapy for anemia, intermittent antibiotic therapy for secondary infections, which are a common cause of death, and periodic surgery for release of digits may reduce morbidity. Tissue-engineered skin grafts containing keratinocytes and fibroblasts are of some benefit. Allogeneic bone marrow transplantation may also be beneficial.

646.5 Pemphigus

Pemphigus Vulgaris

Pemphigus Foliaceus

Clinical Manifestations

The superficial blisters rupture quickly, leaving erosions surrounded by erythema that heal with crusting and scaling (Fig. 646-11). Nikolsky sign is present. Focal lesions are usually localized to the scalp, face, neck, and upper trunk. Mucous membrane lesions are minimal or absent. Pruritus, pain, and a burning sensation are frequent complaints. The clinical course varies but is generally more benign than that of PV. Fogo selvagem, which is endemic in certain areas of Brazil, is identical clinically, histopathologically, and immunologically to pemphigus foliaceus.

Bullous Pemphigoid

646.6 Dermatitis Herpetiformis

Etiology/Pathogenesis

In dermatitis herpetiformis (DH), IgA antibodies are directed at epidermal transglutaminase. Gluten-sensitive enteropathy is found in all patients with DH, although the majority are asymptomatic or have minimal gastrointestinal symptoms (Chapter 330.2). The severity of the skin disease and the responsiveness to gluten restriction do not correlate with the severity of the intestinal inflammation. An antibody to smooth muscle endomysium is found in 70-90% of patients with DH. Ninety percent of patients with the disease express HLA DQ2. HLA DQ2–negative patients with DH usually express HLA DQ8.

646.7 Linear IgA Dermatosis (Chronic Bullous Dermatosis of Childhood)